Switch theme
Sign up to access all valuation multiples
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
2017
63
Last FY Revenue n/a
LTM EBITDA -$311M
$3.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Akero Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$311M.
In the most recent fiscal year, Akero Therapeutics achieved revenue of n/a and an EBITDA of -$247M.
Akero Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Akero Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$311M | XXX | -$247M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$310M | XXX | -$285M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$276M | XXX | -$252M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Akero Therapeutics's stock price is $50.
Akero Therapeutics has current market cap of $4.0B, and EV of $3.3B.
See Akero Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.3B | $4.0B | XXX | XXX | XXX | XXX | $-3.80 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Akero Therapeutics has market cap of $4.0B and EV of $3.3B.
Akero Therapeutics's trades at n/a EV/Revenue multiple, and -13.4x EV/EBITDA.
Equity research analysts estimate Akero Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Akero Therapeutics has a P/E ratio of -14.4x.
See valuation multiples for Akero Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.0B | XXX | $4.0B | XXX | XXX | XXX |
| EV (current) | $3.3B | XXX | $3.3B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -10.6x | XXX | -13.4x | XXX | XXX | XXX |
| EV/EBIT | -10.7x | XXX | -11.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -14.4x | XXX | -15.7x | XXX | XXX | XXX |
| EV/FCF | -13.6x | XXX | -14.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAkero Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $4.5M for the same period.
Akero Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Akero Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Akero Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $4.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Akero Therapeutics acquired XXX companies to date.
Last acquisition by Akero Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Akero Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Akero Therapeutics founded? | Akero Therapeutics was founded in 2017. |
| Where is Akero Therapeutics headquartered? | Akero Therapeutics is headquartered in United States of America. |
| How many employees does Akero Therapeutics have? | As of today, Akero Therapeutics has 63 employees. |
| Who is the CEO of Akero Therapeutics? | Akero Therapeutics's CEO is Dr. Andrew Cheng, M.D.,PhD. |
| Is Akero Therapeutics publicy listed? | Yes, Akero Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Akero Therapeutics? | Akero Therapeutics trades under AKRO ticker. |
| When did Akero Therapeutics go public? | Akero Therapeutics went public in 2019. |
| Who are competitors of Akero Therapeutics? | Similar companies to Akero Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Akero Therapeutics? | Akero Therapeutics's current market cap is $4.0B |
| Is Akero Therapeutics profitable? | Yes, Akero Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Akero Therapeutics? | Akero Therapeutics's last 12 months EBITDA is -$311M. |
| What is the current EV/EBITDA multiple of Akero Therapeutics? | Current EBITDA multiple of Akero Therapeutics is -10.6x. |
| What is the current FCF of Akero Therapeutics? | Akero Therapeutics's last 12 months FCF is -$243M. |
| What is the current EV/FCF multiple of Akero Therapeutics? | Current FCF multiple of Akero Therapeutics is -13.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
